Selective Tyk2 Inhibitor Small Molecule Compound
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases such as rheumatic arthritis and inflammatory skin conditions like psoriasis lack effective and selective inhibitors for the JAK-STAT pathway, particularly for Tyk2 kinase, leading to inadequate control of inflammation and potential side effects.
Innovation Solution
Development of a small molecule compound with high potency and selectivity as a Tyk2 inhibitor, or dual JAK1/Tyk2 inhibitor, designed to target the JAK-STAT pathway, specifically inhibiting Tyk2 kinase to control inflammation and treat autoimmune diseases with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases are used, then inflammation control is achieved, but selectivity and side effect profile are inadequate
Solution Approach 1:
The patent applies local quality by designing a small molecule compound with specific structural features (substituted pyrimidine core with particular R1 groups) that confer selective binding affinity for Tyk2 kinase over other JAK family members. This molecular-level local differentiation enables the drug to target specifically the pathological Tyk2-mediated signaling pathways in autoimmune diseases while sparing other kinases, thereby reducing off-target side effects while maintaining reliable inflammation control
Solution Approach 2:
The patent employs parameter changes by optimizing the IC50 value of the compound against Tyk2 to below 200 nM, representing a quantitative threshold that ensures sufficient potency. Additionally, the compound achieves greater than 10-fold selectivity ratio compared to other JAK kinases, another optimized parameter that collectively enables effective inflammation control with improved safety profile
2Reliability
If JAK1 and JAK3 inhibitors are developed, then autoimmune disease treatment is advanced, but Tyk2 inhibition is neglected leading to incomplete pathway blockade
Solution Approach 1:
The patent applies universality by creating a dual-function inhibitor that can block both JAK1 and Tyk2 kinases within a single molecular entity. The compound's structural design allows it to interact with the ATP-binding sites of multiple JAK family members, particularly JAK1 and Tyk2, thereby providing broad coverage of the JAK-STAT pathway. This multi-target approach ensures more complete pathway blockade and enhanced therapeutic efficacy across different autoimmune conditions that may involve different cytokine signaling pathways
Data Source
AI summary
Provided is a small molecule compound, which is characterized in having the structure represented by the following molecular formula: (I), wherein X1 and X2 are selected from carbon or nitrogen; G1 is a carbocyclic ring or heterocyclic ring having aromaticity; any one or more hydrogen atoms on the ring of G1 are substituted by R1; and R1 is selected from nitrogen-containing groups. The small molecule compound of the present invention can be used as a highly effective and specific JAK kinase inhibitor, specifically a Tyk2 inhibitor; and/or a JAK1 inhibitor, and/or a JAK1/Tyk2 or Tyk2/JAK1, Tyk2/Jak2 dual inhibitor.